Informatie over actuele ontwikkelingen in zowel reguliere als alternatieve en/of aanvullende behandelingen en middelen bij Sarcomen - weke delen kanker en Ewingsarcoma.
Ewing-sarcoom (ES) is de tweede meest voorkomende vorm van primaire botkanker bij kinderen en jonge volwassenen. De overlevingskansen voor lokale vormen van het Ewing sarcoom zijn verbeterd naar percentages van boven de 70% voornamelijk door agressieve chemobehandleingen en lokale bestraling. Aan de andere kant, is er weinig verbetering in de overlevingskansen van patiënten met een recideif van het Ewing sarcoom of met bij de diagnose al uitzaaiingen. Tohc is er wel hoop vooral met stamceltransplantaies en immuuntherapie al of niet aangevuld met hyperthermie.
Klik in linkerkolom voor meer artikelen en informatie ook over weke delen sarcoma's
Chemo bij Ewingsarcoma. Een studie van effecten en resultaten daarmee.
23 oktober 2004: Bron: Pubmed: Pediatr Blood Cancer. 2004 Oct 23; Hier het abstract van een studie die een overzicht geeft van de effecten van chemokuren bij het Ewing Sarcoom bij kinderen.
Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: The Children's Cancer Group (CCG) experience. Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G, Cairo MS. Childrens Hospital of Los Angeles, Los Angeles, California.
BACKGROUND: The prognosis for children with recurrent/refractory sarcomas is poor. We determined the overall response rate (ORR) and overall survival (OS) of children with recurrent/refractory sarcomas who were given ifosfamide, carboplatin, and etoposide (ICE) in three Children's Cancer Group (CCG) phase I/II trials.
PROCEDURE: Children with recurrent/refractory sarcoma were treated with ifosfamide (1,800 mg/m(2)/day on day 0-4), carboplatin (400 mg/m(2)/day on day 0-1), etoposide (100 mg/m(2)/day on day 0-4) and either rhG-CSF (10 mug/kg/day vs. 5 mug/kg/day, CCG-0894, 71 patients), PIXY321 (500-1,000 mug/m(2)/day, CCG-0924, 14 patients), or rhG-CSF (5 mug/kg/day) and IL-6 (2.5-5 mug/kg/day, CCG-0931, 12 patients).
RESULTS: Ninety-seven patients were evaluable for tumor response, 56 male and 41 female, median age 14.1 years (range 2.8-22.5 years). Tumor types were osteosarcoma (OTS) (n = 34), rhabdomyosarcoma (n = 27), Ewing sarcoma (EWS) (n = 21), soft tissue sarcoma-not otherwise specified (n = 5), undifferentiated sarcoma (n = 6), fibrosarcoma (n = 2), peripheral primitive neuroectodermal tumor (n = 1), and extraosseous Ewing (n = 1). The ORR was 51% (27% complete response [CR]). OS at 1 and 2 years was 49% and 28%, respectively. Patients with CR or partial response (PR) had significantly increased 1- and 2-year OS, 71% and 41%, respectively, (P < 0.001). Rhabdomyosarcoma patients with embryonal histology had significant improvement in 1- and 2-year OS: 82% and 46%, respectively, compared with other histologies, (P < 0.005).
CONCLUSIONS: The ORR to ICE reinduction chemotherapy in children with recurrent/refractory sarcoma was 51%. OS of 1 and 2 years appeared significantly improved in patients who had CR or PR following ICE reinduction therapy or who had rhabdomyosarcoma with embryonal histology. (c) 2004 Wiley-Liss, Inc. PMID: 15503297 [PubMed - as supplied by publisher]
